Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income towards Common Stockholders fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.27% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Net Income towards Common Stockholders is -$27.1 million, which was down 120.26% from -$12.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Net Income towards Common Stockholders high stood at $46.9 million for Q1 2025, and its period low was -$35.2 million during Q2 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Net Income towards Common Stockholders had a median value of -$30.3 million in 2024 and averaged -$18.2 million.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Net Income towards Common Stockholders showed a top increase of 246.58% in 2025 and a maximum decrease of 13.50% in 2025.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Net Income towards Common Stockholders stood at -$33.3 million in 2023, then spiked by 140.32% to $13.4 million in 2024, then declined by 13.50% to -$27.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$27.1 million for Q3 2025, versus -$12.3 million for Q2 2025 and $46.9 million for Q1 2025.